CN105878812A - 以金花茶-石斛为原料的解酒饮料及其生产方法 - Google Patents
以金花茶-石斛为原料的解酒饮料及其生产方法 Download PDFInfo
- Publication number
- CN105878812A CN105878812A CN201610456332.XA CN201610456332A CN105878812A CN 105878812 A CN105878812 A CN 105878812A CN 201610456332 A CN201610456332 A CN 201610456332A CN 105878812 A CN105878812 A CN 105878812A
- Authority
- CN
- China
- Prior art keywords
- parts
- camellia nitidissima
- herba dendrobii
- nitidissima chi
- hangover
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 35
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 206010019133 Hangover Diseases 0.000 title abstract description 10
- 241001657422 Camellia petelotii Species 0.000 title abstract 3
- 241000628997 Flos Species 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 239000011858 nanopowder Substances 0.000 claims abstract description 11
- 239000004615 ingredient Substances 0.000 claims abstract description 10
- 241001328788 Camellia nitidissima Species 0.000 claims description 38
- 239000000284 extract Substances 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 13
- 229920001202 Inulin Polymers 0.000 claims description 11
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 11
- 229940029339 inulin Drugs 0.000 claims description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000033228 biological regulation Effects 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- CBMPTFJVXNIWHP-UHFFFAOYSA-L disodium;hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].OP([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O CBMPTFJVXNIWHP-UHFFFAOYSA-L 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 53
- 210000004369 blood Anatomy 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 20
- 210000002784 stomach Anatomy 0.000 abstract description 19
- 230000006870 function Effects 0.000 abstract description 18
- 210000004185 liver Anatomy 0.000 abstract description 17
- 230000002496 gastric effect Effects 0.000 abstract description 14
- 150000004676 glycans Chemical class 0.000 abstract description 8
- 229920001282 polysaccharide Polymers 0.000 abstract description 8
- 239000005017 polysaccharide Substances 0.000 abstract description 8
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 241001523681 Dendrobium Species 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 abstract description 6
- 238000001784 detoxification Methods 0.000 abstract description 6
- 229930003944 flavone Natural products 0.000 abstract description 6
- 235000011949 flavones Nutrition 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 239000011669 selenium Substances 0.000 abstract description 6
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 5
- 229910052711 selenium Inorganic materials 0.000 abstract description 5
- 235000011649 selenium Nutrition 0.000 abstract description 5
- 239000011573 trace mineral Substances 0.000 abstract description 5
- 235000013619 trace mineral Nutrition 0.000 abstract description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 5
- 241000209507 Camellia Species 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 235000018597 common camellia Nutrition 0.000 abstract description 4
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 240000001432 Calendula officinalis Species 0.000 abstract description 3
- 235000005881 Calendula officinalis Nutrition 0.000 abstract description 3
- 230000029142 excretion Effects 0.000 abstract description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 3
- 229930182490 saponin Natural products 0.000 abstract description 3
- 150000007949 saponins Chemical class 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- RYAHJFGVOCZDEI-UFFNCVEVSA-N Dendrobine Chemical compound C([C@H]1CC[C@@H]2[C@@]31C)N(C)[C@@H]3[C@H]1[C@@H](C(C)C)[C@@H]2C(=O)O1 RYAHJFGVOCZDEI-UFFNCVEVSA-N 0.000 abstract description 2
- 230000008827 biological function Effects 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 abstract description 2
- RYAHJFGVOCZDEI-CZKZLRAZSA-N dendrobine Natural products O=C1O[C@@H]2[C@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1 RYAHJFGVOCZDEI-CZKZLRAZSA-N 0.000 abstract description 2
- 210000000232 gallbladder Anatomy 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 108010064851 Plant Proteins Proteins 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 210000002249 digestive system Anatomy 0.000 abstract 1
- 230000003859 lipid peroxidation Effects 0.000 abstract 1
- 235000021118 plant-derived protein Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 20
- 230000035622 drinking Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 241001122767 Theaceae Species 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010000059 abdominal discomfort Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 229910052732 germanium Inorganic materials 0.000 description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000018556 stomach disease Diseases 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241001076416 Dendrobium tosaense Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010067171 Regurgitation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ABTRFGSPYXCGMR-KXQOOQHDSA-N (3R)-beta,psi-caroten-3-ol Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C ABTRFGSPYXCGMR-KXQOOQHDSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YFVGIJBUXMQFOF-PJOVQGMDSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 YFVGIJBUXMQFOF-PJOVQGMDSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- KMOUJOKENFFTPU-UHFFFAOYSA-N Apigenin-7-glucosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-UHFFFAOYSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241001463014 Chazara briseis Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- ACBOFPQSBWBAQR-UHFFFAOYSA-N Cosmosiin Natural products OCC1OC(Oc2cc(O)c3C(=O)C=C(Oc3c2)c4cccc(O)c4)C(O)C(O)C1O ACBOFPQSBWBAQR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- -1 Flavone compound Chemical class 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000594394 Hedyotis Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 240000007171 Imperata cylindrica Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- YFVGIJBUXMQFOF-SAXLCNSLSA-N Linarin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4ccc(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 YFVGIJBUXMQFOF-SAXLCNSLSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241001327284 Sorghastrum nutans Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001062811 Stewartia malacodendron Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047073 Vascular fragility Diseases 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QBYFCXBVWQQXFH-UHFFFAOYSA-N acaciin Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC6OCC(O)C(O)C6O)cc3O2 QBYFCXBVWQQXFH-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- KMOUJOKENFFTPU-QNDFHXLGSA-N apigenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 KMOUJOKENFFTPU-QNDFHXLGSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000006824 bubonic plague Diseases 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940119162 calendula officinalis flower extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001198 cardioexcitatory effect Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009514 rubixanthin Nutrition 0.000 description 1
- 239000000455 rubixanthin Substances 0.000 description 1
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 244000209700 shan ge teng Species 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明公开了以金花茶‑石斛为原料的解酒饮料及其生产方法，该解酒饮料有效成分的原料的重量份如下：金花茶叶或茶花15‑25份，葛根叶或花20‑40份，金盏花15‑20份，铁皮石斛纳米粉10‑20份，白茅根10‑20份，菊花15‑30份。本发明的解酒饮料含有金花茶皂甙、金花茶黄酮、石斛多糖、石斛碱、多种氨基酸、微量元素硒、植物蛋白、维生素等成分，可消酒、清热解毒、镇静、清肺清脑、护肝护胆护胃的功效。其有效成分会在体内迅速分解代谢酒精，促进肝脏解毒、肾脏排泄的功能，还可起到恢复肠胃粘膜和正常菌群，促进消化系统健康，同时具有活血化瘀、降低血糖血压血脂提高免疫能力、抗脂质过氧化、抗肿瘤、抗衰老等生物功能。
Description
技术领域
本发明涉及解酒保健品技术领域，具体是一种以金花茶-石斛为原料具有解酒功能的保健饮料。
背景技术
中国是酒文化王国。自古以来，举凡年节吉日、婚丧嫁娶、庆生奠死、宴亲飨客、洗尘饯行等等，人们生活的方方面面、时时刻刻几乎都离不开酒。饮酒，也是如今人们日常生活的一项重要内容，随着我国市场经济的发展，商业活动日趋频繁，人们在日常应酬中免不了时常饮酒，由于大量饮酒造成的身体不适状况屡见不鲜，饮酒者的身体健康受到威胁。
酒精在体内的代谢过程，主要在肝脏中进行，少量酒精可在进入人体之后，马上随肺部呼吸或经汗腺排出体外，绝大部分酒精在肝脏中先与乙醇脱氢酶作用，生成乙醛，乙醛对人体有害，但它很快会在乙醛脱氢酶的作用下转化成乙酸。乙酸是酒精进入人体后产生的唯一有营养价值的物质，它可以提供人体需要的热量。酒精在人体内的代谢速率是有限度的，如果饮酒过量，酒精就会在体内器官，特别是在肝脏和大脑中积蓄，积蓄至一定程度即出现酒精中毒症状。
酒精的化学成分是乙醇，人们饮酒后，乙醇首先在胃内储留，与胃十二指肠黏膜直接接触。正常的胃黏膜表层上皮细胞和胃小凹清晰可见，分布很均匀，酒精能导致黏液变薄，粘膜上皮细胞坏死脱落，微血管内皮损伤、栓塞，组织缺血血氧坏死，从而引起胃黏膜糜烂或溃疡形成。近年来随着生活水平的提高，饮酒的相对增多，酒精刺激引起的胃炎亦有所增加。
对于醉酒人们的传统做法是喝醋或者喝茶，但效果甚微，主要原因是茶叶中的咖啡碱，茶碱，可可碱等有兴奋心脏的作用，饮酒后喝茶会增加对心脏的刺激，喝醋不但不能解酒，而且对消化道黏膜还会产生损伤。临床上通常使用各类口服西药，不但药效不明显且会对患者产生一些副作用。
金花茶是一种古老的植物，极为罕见，分布极其狭窄，全世界90%的野生金花茶仅分布于中国广西防城港市十万大山的兰山支脉一带，生长于海拔700米以下，数量极少，是世界上稀有的珍贵植物。经检验表明，金花茶属无毒级、含有400多种营养物质、无毒副作用。富含茶多糖、茶多酚、总皂甙、总黄酮、茶色素、咖啡因、蛋白质、维生素B1、B2、维生素C、维生素E、叶酸、脂肪酸、B-胡萝卜素等多种天然营养成份；金花茶含有茶氨酸、苏氨酸等几十种氨基酸，以及富含有多种对人体具有重要保健作用的天然有机锗（Ge）、硒（Se）、钼（M）、锌（Zn）、钒（V）等微量元素，和钾（K）、钙（Ca）、镁（Mg）等宏量元素。民间又称金花茶为“神茶”，国外称之为神奇的东方魔茶，被誉为“植物界大熊猫”、“茶族皇后”。金花茶具有明显的降血糖和尿糖作用，能有效的改善糖尿病“三高”症状。金花茶在有效降低血糖、血压的同时，可有效降低血脂，改善因高血压而引起的各种不适应症状，降低血清中胆固醇和B-脂蛋白，促进胰岛素分泌、增强免疫力、调节血流量，防止动脉粥样硬化，抗菌消炎、清热解毒、通便利尿去湿，增进肝脏代谢、防癌抑制肿瘤生长等。
目前市场上的解酒饮料口味繁多，解酒效果不佳为了口感会加入一些化学调味剂，人们对健康和功效性的要求越来越高。本发明利用金花茶和石斛特有的药用价值，结合其他辅料，制成一种口味独特、解酒功效强，且具有促进肝脏解毒、肾脏排泄、恢复受损胃肠粘膜、重建肠道菌群的功能，起到醒酒、清脑、促进肠胃酒后恢复作用的解酒保健饮料。
发明内容
本发明的目的是利用金花茶特有的功能，加入一些常见的能够食用的植物叶或花，结合石斛对肠胃的调整的效力，克服了传统解酒饮料在酒后肠胃恢复功效性不强的缺陷，具有清脑提神、清凉降火、生津解渴、减脂降压、健胃消食的作用。
本发明是通过以下技术方案实现的：以金花茶-石斛为原料的解酒饮料由有效成分和辅料制成，所述有效成分的原料的重量份如下：金花茶叶或茶花15-25份，葛根叶或花20-40份，金盏花15-20份，铁皮石斛纳米粉10-20份，白茅根10-20份，菊花15-30份。
以上所述的以金花茶-石斛为原料的解酒饮料，所述辅料为菊粉和低聚糖类，加入的总重量份数为5-10；所述低聚糖类包括低聚果糖、低聚木糖、低聚麦芽糖的一种或几种。。
以金花茶-石斛为原料的解酒饮料的生产方法，包括以下工艺步骤：
（1） 将金花茶叶或茶花、葛根叶或花、金盏花、白茅根、菊花除尘洗净，按以上重量份数称取洗净的原料，采用半仿生法提取，即用5-10倍重量的半仿生提取液煮2次，第一次调节溶液pH为4.1-4.6，提取1小时，第二次调节溶液pH为8.4-8.9，提取0.5-1小时，提取液合并过滤，加入铁皮石斛纳米粉和辅料搅拌均匀，制成混合液；
（2）将上述混合液进行分瓶灌装，100℃水浴灭菌，即得到本发明金花茶解酒饮料的成品。
以上所述的以金花茶-石斛为原料的解酒饮料的生产方法中，半仿生法提取是指，用磷酸氢二钠-柠檬酸缓冲溶液调节溶液pH。提取温度为45℃-65℃。
本解酒饮料各组分在传统中医学理论中的作用如下：
金花茶（拉丁学名：Camellia nitidissima C. W. Chi）：金花茶在有效降低血糖、血压的同时，可有效降低血脂，改善因高血压而引起的各种不适应症状，降低血清中胆固醇和B-脂蛋白，促进胰岛素分泌、增强免疫力、调节血流量，防止动脉粥样硬化，抗菌消炎、清热解毒、通便利尿去湿，增进肝脏代谢、防癌抑制肿瘤生长等。金花茶中的总黄酮含量4400mg/kg,
黄酮类化合物具有降血压、降血脂、防止血栓形成、防治心脑血管疾病、增强免疫、降低血管脆性、改善心脑血管血液循环等作用，还可以抗菌及抗病毒，抗氧化、抗衰老，抗辐射，止咳、祛痰，以及抗肝脏毒。硒是人体红细胞中谷胱甘肽酶的成份，他有抗氧化，保护细胞膜，保护心血管的作用。中国科学家还发现，硒是治疗克山病和大骨节病的有效药物，此外，硒还有解毒功能，降低黄曲B1的毒性，对某些化学致癌物质有减毒作用，还能减轻毒素对肝细胞的损害。锗可降低癌细胞的生物电位，改变其生理状态，抑制癌细胞的增值生长，还可诱发人体内抗癌物质的干扰素，能将巨噬细胞诱发变为抗癌细胞，故有人用锗治疗癌症，另外锗对血管硬化，脑血栓，脑出血，肾肝病，胃病，糖尿病，关节炎，慢性神经痛也有明显的疗效。金花茶花的作用，能够收敛止血，主便血；月经过多，对妇女特别有好处。
葛根（拉丁学名：Pueraria omeiensis Wang et Tang ）：别名葛条，甘葛，葛藤，味甘微辛，气清香，性凉，主入脾胃经。有发表解肌，升阳透疹，解热生津之功效。用于治疗脾虚泄泻、热病口渴、主治外感发热，头项痛强，麻疹透发不畅，温病口渴，消渴，酒毒，胸痹心痛等病症。现代研究表明，葛根含有多种人体必须的氨基酸、维生素及黄酮等，具有治疗心脑血管疾病、预防动脉硬化、抗氧化、促进新陈代谢，加强肝脏解毒功能，防止酒精对肝脏的损伤；强化肝胆细胞自身免疫功能，抵抗病毒入侵。在本发明的组方中主要起以下作用：发表退热、生津止渴、解饮酒后口渴，解酒精、解鱼蟹毒；提高肝细胞的再生能力，恢复正常肝脏机能，促进胆汁分泌，防止脂肪在肝脏堆积，有效预防饮酒造成的酒精肝、脂肪肝等作用。
金盏花（拉丁学名：Calendula officinalis L）：金盏花富含多种维生素，尤其是维生素A和维生素C，可预防色素沉淀、增进皮肤光泽与弹性、减缓衰老、避免肌肤松弛生皱。几乎各部位都可以食用；其花瓣有美容之功能，花含类胡萝卜素、番茄烃、蝴蝶梅黄素、玉红黄质、挥发油、树脂、黏液质、苹果酸等。根含苦味质，山金东二醇；种子含甘油酯、蜡醇和生物碱。主要药理作用有：有抗菌、消炎作用；降血脂作用，对肝脏总脂质、胆固醇和三酸甘油也有降低作用；金盏花中的多糖成分有较强的免疫刺激作用；金盏菊花提取物对中枢神经系统有镇静作用，可降低反射兴奋性；静脉注射可降低血压，增强心脏活动，增大心跳振幅，减慢心率；能促进胆汁分泌，加速创伤愈合。欧洲民间有内服金盏菊花治疗胃及十二指肠溃疡、胃炎、肝胆疾患等的习俗。若用于消化道癌肿可减轻中毒症状、改善食欲、睡眠等，亦有用于月经不调者。古埃及人认为金盏花能延缓衷老，印度人则尊奉它为神圣的花。中世纪时人们已将金盏花用于疗伤，更藉以对抗瘟疫和黑死病。
铁皮石斛（拉丁学名：Dendrobium officinale Kimura et Migo）：石斛属多年生草本植物的新鲜或干燥茎。铁皮石斛又名铁皮枫斗、耳环石斛、铁皮兰、黑节草等，为石斛之上品，名列“中华九大仙草”之首。其味甘，性微寒, 归胃、肾经, 具有养阴清热、益胃生津的功效，药用价值历代为人们所推崇。铁皮石斛主要含石斛多糖、生物碱、氨基酸、微量元素和菲类化合物等有效成分，多糖成分可增强机体免疫机能、抗肿瘤、抗衰老、抗疲劳、降血糖。生物碱类成分的药理作用主要表现对心血管、胃肠道作用及退热止痛等。铁皮石斛中含有的菲类化合物均具有抗癌活性，可增强巨噬细胞的吞噬作用，能促进T细胞生长和淋巴细胞产生移动抑制因子，明显提升外周白细胞，起到增强免疫功能的作用。现代研究表明，铁皮石斛具有增强机体免疫力、抗肿瘤、促进消化液分泌、抑制血小板凝集、降血脂、降血糖、抗氧化、抗衰老和退热止痛等药理作用。铁皮石斛的养胃生津作用较强，历代医家称其“久服厚胃”，“平胃气，长肌肉”，“理胃气，清胃火”。因此，人们还将它称之为“肠胃药”，是治疗胃脘痛、上腹胀满的常用药物。能促进胃液的分泌，增强胃的排空能力，帮助消化，并能保护胃黏膜的损伤，明显改善功能性消化不良者症状。石斛还能使人血中的促胃液素浓度升高，而促胃液素是由分布在胃窦及小肠上部黏膜的G细胞分泌的，有益于慢性萎缩性胃炎的治疗。石斛对脾胃病中的致病菌—幽门螺杆菌有较好的抑制作用，有助于治疗萎缩性胃炎、浅表性胃炎等幽门螺杆菌阳性的病症，是脾胃病的理想药物。
白茅根（拉丁学名：Imperata cylindrica）：别称丝茅草、茅草、白茅草，为禾本科植物多年生草本白茅的根茎。《神农本草经》曰：“茅根，味甘寒。主劳伤虚赢，补中益气，除瘀血血闭寒热，利小便。其苗，主下水。”《名医别录》曰：“茅根，无毒。主下五淋，除客热在肠胃，止渴，坚筋，妇人崩中。久服利人。”具有凉血止血，清热解毒之功效。现代药理学认为，它含淀粉和多量蔗糖、葡萄糖以及少量果糖、木糖、柠檬酸、草酸、苹果酸；其根茎还含甘露醇、薏苡素和芦竹素等成分。它所含丰富的钾盐有良好的利尿作用，煎液对某些痢疾杆菌有明显的抑菌作用。现代临床研究证实本品具有良好的止血、利尿、抗感染的作用，对病毒性肝炎疗效亦颇佳，众多医家都认为它清热利水而不伤肾。
菊花（拉丁学名：Dendranthema morifolium（Ramat.
）Tzvel.）：别称寿客、金英、黄华、秋菊、陶菊、日精、女华、延年、隐逸花，属菊目菊科多年生草本植物，主要成分为挥发油、黄酮类、三萜类及氨基酸、微量元素等，并富含挥发油、菊酮、龙脑、龙脑己酸酯及水苏碱、刺槐甙、木樨草甙、大波斯菊甙、腺膘呤、胆碱、葡萄糖甙等物质成分，具有养肝明目、散风清热、消咳止痛等多种药理活性，对于降低血压、预防高血脂、抗菌、抗病毒、抗炎、抗衰老、治疗冠心病、头痛眩晕、目赤肿痛、风热感冒、咳嗽等病症效果显著。汉朝《神农本草经》记载：“菊花久服能轻身延年”。菊花具有疏风、清热、明目、解毒之功效，并对葡萄球菌、链球菌及绿脓杆菌有抑制及杀灭作用。本发明可以采用黄菊或白菊。
菊粉（拉丁学名：Synanthrin）：菊粉是植物中储备性多糖，在自然界中的分布十分广泛，某些真菌和细菌中也含有菊粉，但其主要来源是植物。菊粉是一种天然存在的膳食纤维，在人体内可延长碳水化合物的供能时间而又不显著提高血糖水平，代谢不需要胰岛素，有助于减少糖尿病人对胰岛素的依赖性和需要，控制血糖水平。对肠道双歧杆菌、乳酸杆菌的上涨还具有明显的促进作用。摄入一定量的菊粉能徐进矿物元素尤其是磷酸钙的吸收量，促进钙在骨骼中的吸收和沉淀，防治骨质疏松。另外菊粉还具有促进消化、排便和新陈代谢，去除湿疹、美肤、减肥、护肝、抗抑郁的功能，并且不提供能量，适合糖尿病人食用。
由于采用了上述技术方案，本发明与现有技术相比具有如下有益效果：
本发明的解酒饮料中，金花茶、葛根、白茅根、菊花联合使用可以明显增强金花茶的解酒作用，同时提高肝脏乙醇脱氢酶 （alcoholdehydrogenase,ADH）和乙醛脱氢酶的活性，其解酒作用与增强乙醇的生物转化有关。发挥协同解酒作用，对急、慢性酒精中毒均能发挥一定的解酒作用。此外，还具有抗脂质过氧化作用，对肝损伤、肝纤维化以及肝硬化亦具有一定的防治作用。再加上白茅根的协同作用，使解酒作用增强，发挥健胃消食功能，以缓解饮酒过程中过食肥甘引起的 肠胃负担；而葛根又能增强肠胃的上下开阖功能；菊花护肝明目，清热解毒，可解酒后虚火。
此外，君药均具有抗脂质过氧化作用，对肝损伤、肝纤维化以及肝硬化可有防治作用。再加上铁皮石斛多糖可修复酒后胃肠粘膜的损伤，恢复因饮酒导致的肠道菌群失调，重建健康的肠道微生物系统。白茅根使解酒作用增强，发挥健胃消食功能，以缓解饮酒过程中过食肥甘引起的肠胃负担；而葛根又能增强肠胃的上下开阖功能；菊花护肝明目，清热解毒，可解酒后虚火。
本发明的解酒饮料含有金花茶皂甙、金花茶黄酮、石斛多糖、石斛碱、多种氨基酸、微量元素、植物蛋白、维生素等成分，具有缓解酒后发热烦渴，呕逆吐酸等症状，具有憎寒、壮热、解酒醒脾、酒痢、饮食不思、胸膈饱胀、发呃、呕吐酸痰、酒毒伤胃、消热、清肺等功效。其有效成分会在体内激活酒精代谢通路的相关酶类，使得机体迅速分解代谢酒精，促进肝脏解毒、肾脏排泄的功能，起到醒酒、清脑的作用，石斛则可起到恢复肠胃粘膜和正常菌群，促进消化系统健康，从根本上解决醉酒后机体功能修复的问题。本发明的解酒饮料充分利用了我国传统中医药理论，完全采用大自然药食两用中药，是真正绿色解酒饮料，还具有提高免疫能力、抗脂质过氧化、抗肿瘤、抗衰老等生物功能。
本发明的生产方法采用半仿生提取法，半仿生提取法（简称SBE）是近几年提出的新方法。它是从生物药剂学的角度，将整体药物研究法与分子药物研究法相结合，模拟口服药物经胃肠道转运吸收的环境，采用活性指导下的导向分离方法；是经消化道口服给药的制剂设计的一种新的提取工艺。半仿生提取法的主要特点，一是提取过程符合中医配伍和临床用药的特点和口服药物在胃肠道转运吸收的特点。二是在具体工艺选择上，既考虑活性混合成分又以单体成分作指标，这样不仅能充分发挥混合物的综合作用，又能利用单体成分控制中药制剂的质量。三是有效成分损失少。采用这种方法提取出来的溶液活性成分丰富、不被破坏，且更易被人体吸收。
具体实施方式
实施例
1
以金花茶-石斛为原料的解酒饮料的有效成分的重量份数为：金花茶叶15份、葛根叶40份、金盏花20份，铁皮石斛纳米粉10份，白茅根10份，菊花15份；辅料的重量份数为菊粉3份，低聚木糖2份。
其生产方法的工艺步骤如下：
将金花茶叶、葛根叶、金盏花、白茅根、菊花除尘洗净，按以上重量份数称取洗净的原料，采用半仿生法提取，即用5倍重量的磷酸氢二钠-柠檬酸缓冲溶液提取液45℃下煮2次，第一次调节pH为4.6，提取1小时、第二次调节pH为8.4，提取0.5小时，提取液合并过滤，加入铁皮石斛纳米粉和辅料搅拌均匀，制成混合液；
将上述混合液进行分瓶灌装，100℃水浴灭菌，即得到本发明解酒保健饮料的成品。
实施例
2
以金花茶-石斛为原料的解酒饮料的有效成分的重量份数为：金花茶叶25份、葛根花20份、金盏花18份、铁皮石斛纳米粉14份、白茅根20份，菊花30份；辅料的重要份数为菊粉6份，低聚果糖2份、低聚麦芽糖2份。
其生产方法的工艺步骤如下：
将金花茶叶、葛根花、金盏花、白茅根、菊花除尘洗净，按以上重量份数称取洗净的原料，采用半仿生法提取，即用10倍重量的磷酸氢二钠-柠檬酸缓冲溶液提取液65℃下煮2次，第一次调节pH为4.1，提取1小时、第二次调节pH为8.9，提取1小时，提取液合并过滤，加入铁皮石斛纳米粉和辅料搅拌均匀，制成混合液；
将上述混合液进行分瓶灌装，100℃水浴灭菌，即得到本发明解酒保健饮料的成品。
实施例
3
以金花茶-石斛为原料的解酒饮料的有效成分的重量份数为：金花茶花20份、葛根叶25份、金盏花15份、铁皮石斛纳米粉20份、白茅根17份，菊花20份；辅料的重量份数为菊粉3份，低聚果糖2份、低聚木糖1份、低聚麦芽糖1份。
其生产方法的工艺步骤如下：
将金花茶花、葛根叶、金盏花、白茅根、菊花除尘洗净，按以上重量份数称取洗净的原料，采用半仿生法提取，即用8倍重量的磷酸氢二钠-柠檬酸缓冲溶液提取液50℃下煮2次，第一次调节pH为4.5，提取1小时、第二次调节pH为8.5，提取0.7小时，提取液合并过滤，加入铁皮石斛纳米粉和辅料搅拌均匀，制成混合液；
将上述浓缩液进行分瓶灌装，100℃水浴灭菌，即得到本发明解酒保健饮料的成品。
应用实施例
1
张某，男，52岁，钦州市某政府部门领导，因应酬饮53°白酒550ml，饮后浑身燥热，步态不稳、言语错乱、呕吐、肠胃不适、头晕不止，家人为其服用该解酒饮料400ml，休息之后症状缓解， 约80分钟后，言语步态恢复正常。次日饮食恢复正常，无明显肠胃不适发生。
应用实施例
2
宋某，男，41岁，崇左市某建材公司经理，同学聚餐饮酒50°白酒420ml至酒醉，头晕乏力，吐酸水，嗜睡，并且不自主流口水，之后同学帮助其服用了该解酒饮料500ml，60分钟后头疼明显减轻，不再呕吐，继续服用300ml，休息50分钟后头晕感消失，恢复正常。一周后回访了解，自诉较以往胃口更快恢复正常。
应用实施例
3
方某，男，18岁，南宁市人，因高考落榜喝闷酒，饮45°白酒400ml至酒醉，肠胃不适，头痛呕吐，多汗，家人让其服用了该解酒饮料400ml，2小时后肠胃不适缓解，头痛减轻，继续服用400ml，休息80分钟后呕吐感消失，服用该保健饮料一周，食欲恢复。
Claims (4)
1.以金花茶-石斛为原料的解酒饮料，其特征在于，由有效成分和辅料制成，所述有效成分的原料的重量份如下：金花茶叶或茶花15-25份，葛根叶或花20-40份，金盏花15-20份，铁皮石斛纳米粉10-20份，白茅根10-20份，菊花15-30份。
2.如权利要求1所述的以金花茶-石斛为原料的解酒饮料，其特征在于：所述的辅料为菊粉和低聚糖类，加入的总重量份数为5-10；所述低聚糖类包括低聚果糖、低聚木糖、低聚麦芽糖的一种或几种。
3.一种以金花茶-石斛为原料的解酒饮料的生产方法，其特征在于：包括以下工艺步骤：
将金花茶叶或茶花、葛根叶或花、金盏花、白茅根、菊花除尘洗净，按以上重量份数称取洗净的原料，采用半仿生法提取，即用5-10倍重量的半仿生提取液煮2次，第一次调节溶液pH为4.1-4.6，提取1小时，第二次调节溶液pH为8.4-8.9，提取0.5-1小时，提取液合并过滤，加入铁皮石斛纳米粉及辅料搅拌均匀，制成混合液；
将上述混合液进行分瓶灌装，100℃水浴灭菌，即得到本发明金花茶解酒饮料的成品。
4.如权利要求3中所述的以金花茶-石斛为原料的解酒饮料的生产方法，其特征在于：其中半仿生法提取是指，用磷酸氢二钠-柠檬酸缓冲溶液调节溶液pH，提取温度为45℃-65℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610456332.XA CN105878812B (zh) | 2016-06-22 | 2016-06-22 | 以金花茶-石斛为原料的解酒饮料及其生产方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610456332.XA CN105878812B (zh) | 2016-06-22 | 2016-06-22 | 以金花茶-石斛为原料的解酒饮料及其生产方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105878812A true CN105878812A (zh) | 2016-08-24 |
| CN105878812B CN105878812B (zh) | 2019-12-27 |
Family
ID=56730313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610456332.XA Active CN105878812B (zh) | 2016-06-22 | 2016-06-22 | 以金花茶-石斛为原料的解酒饮料及其生产方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105878812B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106962934A (zh) * | 2017-04-27 | 2017-07-21 | 合肥工业大学 | 一种以茶皂素为主体的解酒饮料 |
| CN107836549A (zh) * | 2017-12-15 | 2018-03-27 | 梁永平 | 一种凉茶及其采用半仿生提取的制备方法 |
| CN111759956A (zh) * | 2020-07-08 | 2020-10-13 | 广西农业职业技术学院 | 一种以白茅根-红糟酸为原料的解酒含片及其生产方法 |
| CN115715558A (zh) * | 2022-11-21 | 2023-02-28 | 淮阴工学院 | 一种解酒护肝的固体饮料及其制备方法 |
| CN115715558B (zh) * | 2022-11-21 | 2024-10-25 | 淮阴工学院 | 一种解酒护肝的固体饮料及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100803A (zh) * | 2009-12-22 | 2011-06-22 | 沈献礼 | 一种具有解酒功能的保健品组合物及其制备方法 |
-
2016
- 2016-06-22 CN CN201610456332.XA patent/CN105878812B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100803A (zh) * | 2009-12-22 | 2011-06-22 | 沈献礼 | 一种具有解酒功能的保健品组合物及其制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| 吴晓冰等: "《解酒醒酒与护肝养胃》", 31 August 2007, 金盾出版社 * |
| 葛静: "《春夏秋冬花草茶》", 30 June 2014, 天津科学技术出版社 * |
| 邓莉兰: "《风景园林树木学》", 31 March 2010, 中国林业出版社， * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106962934A (zh) * | 2017-04-27 | 2017-07-21 | 合肥工业大学 | 一种以茶皂素为主体的解酒饮料 |
| CN107836549A (zh) * | 2017-12-15 | 2018-03-27 | 梁永平 | 一种凉茶及其采用半仿生提取的制备方法 |
| CN111759956A (zh) * | 2020-07-08 | 2020-10-13 | 广西农业职业技术学院 | 一种以白茅根-红糟酸为原料的解酒含片及其生产方法 |
| CN115715558A (zh) * | 2022-11-21 | 2023-02-28 | 淮阴工学院 | 一种解酒护肝的固体饮料及其制备方法 |
| CN115715558B (zh) * | 2022-11-21 | 2024-10-25 | 淮阴工学院 | 一种解酒护肝的固体饮料及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105878812B (zh) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100574097B1 (ko) | 숙취해소 및 간기능 개선용 식품 조성물 | |
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
| CN102038260B (zh) | 中药解酒保健饮料及其制备方法 | |
| CN104286273A (zh) | 铁皮石斛的用途及其茶叶制品 | |
| CN105341588A (zh) | 一种解酒护肝、保胃、清热润肺饮品及其制备方法 | |
| CN103203008A (zh) | 用于解酒的药物组合物及其制备方法 | |
| CN107156828A (zh) | 一种适用于炎性肠病患者的全营养配方食品 | |
| CN101658618B (zh) | 一种解酒护肝复方制剂及应用 | |
| CN105381306A (zh) | 一种缓解酒精性肝、脑和心损伤的袋泡茶组合物 | |
| CN105878812A (zh) | 以金花茶-石斛为原料的解酒饮料及其生产方法 | |
| CN107412665B (zh) | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 | |
| CN103125937A (zh) | 一种解酒护肝剂及其制备方法 | |
| CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
| CN104115960A (zh) | 一种鲜芦根凉茶饮料 | |
| CN107432915A (zh) | 一种治疗脂肪肝、前列腺炎、糖尿病、高血压、肺炎、胃肠炎的药物 | |
| CN104586977A (zh) | 苦丁茶颗粒剂及其生产方法 | |
| CN101745042B (zh) | 一种具有解酒保肝作用的组合物及其制备方法 | |
| CN106072636A (zh) | 以金花茶为原料的解酒含片及其生产方法 | |
| CN105998797A (zh) | 以金花茶-石斛为原料的解酒颗粒剂及其生产方法 | |
| JP2005154411A (ja) | 二日酔い防止・除去用組成物 | |
| KR20210041387A (ko) | 갈화 추출물 및 차전자피 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
| CN104474406A (zh) | 滋阴润肺养生中药酒及制备方法 | |
| KR20200061285A (ko) | 가랑갈 추출물을 포함하는 혈액순환 및 혈관질환 예방용 식품 조성물 | |
| CN110693931A (zh) | 一种养生牛蒡咀嚼片配方及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231220 Address after: 530007 No. 174, University Road, XiXiangTang District, Nanning City, Guangxi Zhuang Autonomous Region Patentee after: GUANGXI ACADEMY OF AGRICULTURAL SCIENCES Address before: 530007, 174 East University Road, the Guangxi Zhuang Autonomous Region, Nanning Patentee before: AGRICULTURAL PRODUCTS PROCESSING INSTITUTE, GUANGXI ACADEMY OF AGRICULTURAL SCIENCES |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240122 Address after: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Country or region after: China Address before: 530007 No. 174, University Road, XiXiangTang District, Nanning City, Guangxi Zhuang Autonomous Region Patentee before: GUANGXI ACADEMY OF AGRICULTURAL SCIENCES Country or region before: China Effective date of registration: 20240122 Address after: No. 101, Gate 3, Building 11, Huifeng Garden, Jianguo Street, Xianshuigu Town, Jinnan District, Tianjin, 300000 Patentee after: Han Fengchao Country or region after: China Address before: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Country or region before: China |